U.S. MARKETS FOR SKIN REPLACEMENTS AND SUBSTITUTES AND ACTIVE WOUND REPAIR MODULATORS

121 Pages | 22 Exhibits | 2013 Analysis | Forecasts Through 2016

OVERVIEW:
In 2011, U.S. sales of tissue-engineered skin replacements/substitutes and active wound repair modulators totaled approximately $404.8 million; of this, skin replacements/substitutes (including traditional products that are used for a broad range of indications including cosmetic and reconstructive surgery, as well as future introductions of tissue-engineered skin replacement/substitute products for a variety of wound healing applications) accounted for an estimated 78.1% of sales, and active wound repair modulators (consisting only of growth factors, the only FDA approved product in this market to date) accounted for the remaining 21.9% of sales. Over the forecast period covered by this report, combined sales are expected to increase at a compound annual rate of 6.3%, reaching an estimated $549.7 million in the year 2016.

This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. skin replacements/substitutes and active wound repair modulators market. Topics discussed in this report include an overview of clinical issues in wound management, tissue-engineered skin replacements/substitutes (e.g., epidermal equivalents, dermal equivalents, and multilayer equivalents), active wound repair modulators (e.g., growth factors, gene therapy agents, stem cells, antibiotics/anti-infectives, hormones, matrix metalloproteinase inhibitors, and neuropeptides), analyses of market forecasts and market shares, and profiles of leading competitors and products in these markets.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Tissue-Engineered Skin Replacements/Substitutes
ii. Active Wound Repair Modulators
	a. Growth Factors
	b. Gene Therapy
	c. Stem Cells
iii. Combined Market Forecast

Exhibit ES-1: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2011-2016
Exhibit ES-2: Growth Factors, Market Forecast, 2011-2016
Exhibit ES-3: Tissue-Engineered Skin Replacements/Substitutes and Active Wound Repair Modulators, Combined Market Forecast, 2011-2016

1. CLINICAL ISSUES IN WOUND MANAGEMENT

1.1 Physiology of Wound Closure
	1.1.1 Layers of the Skin and Supporting Structures
		1.1.1.1 Epidermis
		1.1.1.2 Dermis
		1.1.1.3 Hypodermis
		1.1.1.4 Fascia
		1.1.1.5 Muscle
		1.1.1.6 Bone
	1.1.2 Wound Closure Process
		1.1.2.1 Hemostasis
		1.1.2.2 Inflammation
		1.1.2.3 Proliferation
		1.1.2.4 Remodeling Phase
1.2 Factors Affecting Wound Closure
	1.2.1 Intrinsic Factors
		1.2.1.1 Age and Chronic Illness
		1.2.1.2 Body Composition
		1.2.1.3 Nutritional Status
	1.2.2 Extrinsic Factors
		1.2.2.1 Ambient Temperature
		1.2.2.2 Desiccation/Hydration
		1.2.2.3 Infection
		1.2.2.4 Maceration
		1.2.2.5 Medication and Other Treatment Modalities
		1.2.2.6 Necrotic Tissue and Debris
		1.2.2.7 Oxygen
		1.2.2.8 Stress
		1.2.2.9 Wound Creation and Depth
		1.2.2.10 Wound Closure Techniques
		1.2.2.11 Other Extrinsic Factors
	1.2.3 Complications of Wound Healing
		1.2.3.1 Scarring
		1.2.3.2 Bleeding
1.3 Wound Types
	1.3.1 Illness-Related Wounds
		1.3.1.1 Etiology
			1.3.1.1.1 Arterial Ulcers
			1.3.1.1.2 Diabetic Ulcers
			1.3.1.1.3 Venous Ulcers
		1.3.1.2 Epidemiology
	1.3.2 Pressure Ulcers
		1.3.2.1 Etiology
		1.3.2.2 Epidemiology
	1.3.3 Surgical Wounds
		1.3.3.1 Etiology
		1.3.3.2 Epidemiology
	1.3.4 Traumatic Wounds
		1.3.4.1 Etiology
			1.3.4.1.1 Abrasions, Contusions, and Lacerations
			1.3.4.1.2 Amputations
			1.3.4.1.3 Burns
		1.3.4.2 Epidemiology
		
Exhibit 1-1: The Skin's Layers and Supporting Structures
Exhibit 1-2: Phases of the Wound Closure Process
Exhibit 1-3: Intrinsic and Extrinsic Factors Affecting Wound Closure
Exhibit 1-4: Illness-Related Wounds, Facts and Figures, 1996-2006, and 2009
Exhibit 1-5: Pressure Ulcers, Facts and Figures, 1996-2006, and 2009
Exhibit 1-6: Stages of Pressure Ulcers
Exhibit 1-7: Surgical Wounds, Facts and Figures, 1996-2006, and 2009
Exhibit 1-8: Lacerations and Other Types of Traumatic Wounds, Facts and Figures, 1996-2006, and 2009
Exhibit 1-9: Amputations, Facts and Figures, 1996-2006, and 2009
Exhibit 1-10: Burns, Facts and Figures, 1996-2006, and 2009
Exhibit 1-11: Classification of Burns, by Mechanism of Injury
Exhibit 1-12: Classification of Burns, by Extent of Injury

2. TISSUE-ENGINEERED SKIN REPLACEMENTS AND SUBSTITUTES

2.1 Allografts
2.2 Autografts
2.3 Xenografts
2.4 Autologous and Tissue-Engineered Skin Replacements/Substitutes
	2.4.1 Epidermal Equivalent Products
	2.4.2 Dermal Equivalent Products
	2.4.3 Multilayer Equivalent Products
2.5 Market Forecast
2.6 Competitive Analysis

Exhibit 2-1: 2013, Selected Current and Emerging Tissue-Engineered Skin Replacements and Substitutes
Exhibit 2-2: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2011-2016
Exhibit 2-3: 2011, Tissue-Engineered Skin Replacements and Substitutes Market, Share by Supplier

3. ACTIVE WOUND REPAIR MODULATORS

3.1 Growth Factors
	3.1.1 Growth Factor Classification
		3.1.1.1 Fibroblast Growth Factors
		3.1.1.2 Transforming Growth Factors
		3.1.1.3 Epidermal Growth Factors
		3.1.1.4 Platelet-Derived Growth Factors
		3.1.1.5 Insulin-Like Growth Factors
		3.1.1.6 Keratinocyte Growth Factors
		3.1.1.7 Vascular Endothelial Growth Factors
		3.1.1.8 Autologous Growth Factors
			3.1.1.8.1 Arteriocyte Medical Systems
			3.1.1.8.2 Biomet
			3.1.1.8.3 Cytomedix
			3.1.1.8.4 Harvest Technologies/Terumo
		3.1.1.9 Summary of Angiogenic Growth Factors
	3.1.2 Competitors and Products
	3.1.3 Market Forecast
3.2 Gene Therapy Agents
3.3 Stem Cells
	3.3.1 Types of Stem Cells
		3.3.1.1 Embryonic Stem Cells
		3.3.1.2 Adult Stem Cells
		3.3.1.3 Cord Blood Stem Cells
	3.3.2 The Role of Stem Cells in Wound Healing
	3.3.3 Market Status
3.4 Other Active Wound Repair Modulators and Pharmaceuticals
	3.4.1 Antibiotics and Anti-Infectives
	3.4.2 Hormones
	3.4.3 Matrix Metalloproteinase Enzyme Inhibitors
	3.4.4 Neuropeptides in Diabetic Wounds
	3.4.5 Other Products
	
Exhibit 3-1: Selected Growth Factors in Development for Wound Healing Applications
Exhibit 3-2: The Angiogenesis Process
Exhibit 3-3: 2012, Selected Angiogenic Growth Factors
Exhibit 3-4: Growth Factors, Market Forecast, 2011-2016

4. COMPANY PROFILES

4.1 Biomet, Inc.
4.2 Forticell Bioscience, Inc.
4.3 Genentech, Inc./F. Hoffmann-La Roche LTD
4.4 Genzyme Corporation/Sanofi SA
4.5 Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
4.6 LifeCell Corporation/Kinetic Concepts, Inc.
4.7 Organogenesis, Inc.
4.8 Smith & Nephew PLC
4.9 TEI Biosciences, Inc.

APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. Altrika LTD/Adiposet LTD
  2. Arteriocyte Medical Systems, Inc.
  3. Avita Medical LTD
  4. Baxter Healthcare/Baxter International, Inc.
  5. Biomet, Inc.
  6. Corthera, Inc./Novartis AG
  7. Cubist Pharmaceuticals, Inc.
  8. Cytomedix, Inc.
  9. Derma Sciences, Inc.
  10. Forticell Bioscience, Inc.
  11. Genentech, Inc./F. Hoffman-La Roche LTD
  12. Genzyme Corporation/Sanofi SA
  13. Harvest Technologies, Inc./Terumo Corporation
  14. Healthpoint Biotherapeutics LTD/Smith & Nephew PLC
  15. Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
  16. Kaken Pharmaceutical Co. LTD
  17. KeraCure, Inc.
  18. Kuros Biosurgery AG
  19. LifeCell Corporation/Kinetic Concepts, Inc.
  20. Olympus Corporation
  21. Organogenesis, Inc.
  22. Promethean LifeSciences, Inc.
  23. RegeneRx Biopharmaceuticals, Inc.
  24. Regenicin, Inc.
  25. Sanofi SA
  26. Shire Regenerative Medicine, Inc./Shire PLC
  27. Smith & Nephew PLC
  28. Stratatech Corporation
  29. Systagenix Wound Management LTD
  30. TEI Biosciences, Inc.
  31. Theravance, Inc.
  32. Wright Medical Technology, Inc./Wright Medical Group, Inc.
Contact Us

Need help finding medtech research? Let us help you!